These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19043443)

  • 1. Trial watch : Progress for Phase III cancer vaccines.
    Nat Rev Drug Discov; 2008 Dec; 7(12):966-7. PubMed ID: 19043443
    [No Abstract]   [Full Text] [Related]  

  • 2. [Non-Hodgkin lymphoma becomes curable].
    Krankenpfl J; 2005; 43(1-3):40-1. PubMed ID: 15912832
    [No Abstract]   [Full Text] [Related]  

  • 3. Lymphoma vaccine trial: one step forward in long trek.
    Schmidt C
    J Natl Cancer Inst; 2009 Sep; 101(18):1228-9, 1232. PubMed ID: 19738162
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma.
    Reinis M
    Curr Opin Mol Ther; 2007 Jun; 9(3):291-8. PubMed ID: 17608028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure.
    Longo DL
    J Natl Cancer Inst; 2006 Sep; 98(18):1263-5. PubMed ID: 16985240
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma.
    Bendandi M
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):65-72. PubMed ID: 12113135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspective of clinical research in follicular NHL: interaction between science and industry.
    Fine G; Horning S
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):313-21. PubMed ID: 21658627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer vaccines: will we ever learn?
    Johnson RS; Walker AI; Ward SJ
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):67-74. PubMed ID: 19105708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic idiotype vaccines for non-Hodgkin's lymphoma.
    Timmerman JM
    Adv Pharmacol; 2004; 51():271-93. PubMed ID: 15464914
    [No Abstract]   [Full Text] [Related]  

  • 10. Special report: vaccines for the treatment of prostate cancer.
    Technol Eval Cent Assess Program Exec Summ; 2010 Apr; 24(6):1-2. PubMed ID: 20575182
    [No Abstract]   [Full Text] [Related]  

  • 11. Trial watch: pivotal oncology trials: outlook for Q2 2009.
    Nehring R
    Nat Rev Drug Discov; 2009 Apr; 8(4):266. PubMed ID: 19337264
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.
    Yáñez R; Barrios Y; Ruiz E; Cabrera R; Díaz-Espada F
    J Immunother; 2008 Apr; 31(3):310-2. PubMed ID: 18317357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of vaccination in the adjuvant treatment of cancer of the kidney].
    Fayette J
    Bull Cancer; 2004 Mar; 91(3):211. PubMed ID: 15171044
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic cancer vaccines.
    Pijpers F; Faint R; Saini N
    Nat Rev Drug Discov; 2005 Aug; 4(8):623-4. PubMed ID: 16106585
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic cancer vaccines on trial.
    Reichert JM; Paquette C
    Nat Biotechnol; 2002 Jul; 20(7):659-63. PubMed ID: 12089545
    [No Abstract]   [Full Text] [Related]  

  • 16. Oncophage cancer vaccine shows promise in clinical trials.
    Oncology (Williston Park); 2003 Aug; 17(8):1070, 1094. PubMed ID: 12966675
    [No Abstract]   [Full Text] [Related]  

  • 17. Technical challenges facing therapeutic cancer vaccines.
    Ward S; Copier J; Dalgleish A
    Curr Opin Drug Discov Devel; 2008 Mar; 11(2):168-77. PubMed ID: 18283604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas.
    Reinis M
    Curr Opin Mol Ther; 2008 Oct; 10(5):526-34. PubMed ID: 18830928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1,408 cases.
    Graff-Baker A; Roman SA; Thomas DC; Udelsman R; Sosa JA
    Surgery; 2009 Dec; 146(6):1105-15. PubMed ID: 19958938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.